Friday, July 29, 2011

Friday, July 22, 2011

New anti-cancer drugs plus chemo for breast cancer shows promise: Study

 New anti-cancer drugs plus chemo for breast cancer shows promise: Study...








ABT-737

                                                        


Docetaxel

Thursday, July 21, 2011

FDA approves AstraZeneca's anti-clotting drug Brilinta


 In continuation of my update on  Ticagrelor (Brilinta)......
FDA approves AstraZeneca's anti-clotting drug  Brilinta

Sunday, July 17, 2011

Tocotrienol could help reduce stroke damage

In continuation of my update on the benefits of  Vitamin  E


Tocotrienol could help reduce stroke damage

Saturday, July 16, 2011

Grape seed polyphenols may help prevent Alzheimer's disease

 In continuation of my update on the usefulness of polyphenols....
Grape polyphenols are also called Vineatrols (see structure : vineatrol / trans-resveratrol)



Tuesday, July 12, 2011

Sunday, July 10, 2011

FDA Approves Xarelto (rivaroxaban) to Prevent Deep Vein Thrombosis

We  know that, Rivaroxaban (structure below BAY 59-7939) is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceuticals. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible....


Now FDA Approves Xarelto (rivaroxaban) to Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery....

More....

Saturday, July 9, 2011

Thursday, July 7, 2011

Pharmasset receives U.S. patent titled 'Nucleoside Phosphoramidate Prodrugs'

Pharmasset receives U.S. patent titled 'Nucleoside Phosphoramidate Prodrugs'

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease



We know that Bardoxolone methyl (see the structurealso known as “RTA 402” and “CDDO-methyl ester) is an orally-available first-in-class synthetic triterpenoid belonging to the antioxidant inflammation modulator (AIM) class. It is the most potent known inducer of the Nrf2 pathway to enter clinical development and works to suppress both oxidative stress and inflammation.......